Speciality: Oncology
Description:
In this insightful presentation, renowned oncologist Dr. Nagender Sharma delves into the evolving landscape of advanced urothelial carcinoma treatment. With a focus on evidence-based strategies, Dr. Sharma welcomes viewers to explore the latest advancements, clinical trial insights, and personalized approaches that are reshaping patient care. He emphasizes the importance of integrating immunotherapy, targeted therapies, and chemotherapy while addressing challenges like resistance mechanisms and biomarker-driven decision-making. This video serves as a comprehensive guide for clinicians seeking to optimize outcomes in this complex malignancy.
Dr. Sharma meticulously examines cutting-edge therapies such as immune checkpoint inhibitors, antibody-drug conjugates (e.g., enfortumab vedotin), and FGFR inhibitors, highlighting their roles in first-line and subsequent treatments. He discusses real-world applications of combination regimens, patient selection criteria, and the impact of molecular profiling on tailoring therapies. Additionally, he sheds light on emerging trends, including adaptive clinical trial designs and the potential of novel biomarkers to refine prognostic accuracy. His analysis balances optimism with pragmatism, acknowledging hurdles like toxicity management and access disparities.
Concluding with a forward-looking perspective, Dr. Nagender Sharma underscores the collaborative effort required to translate scientific breakthroughs into tangible survival benefits for patients. Viewers are encouraged to watch the full video to gain actionable insights and stay abreast of this rapidly advancing field. Don’t miss this opportunity to learn from a leading expert. Subscribe for future updates and deepen your understanding of oncology’s most pressing challenges.
See More Webinars @ Hidoc Webinars
1.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
2.
Cancer Patients' Depression May Be Helped by Psilocybin.
3.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
4.
Coupling dye and fiducial marking can improve precision in pulmonary nodule surgical resection
5.
Providing essential cancer care to rural communities
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
3.
Phosphate Vs. Phosphorus: What Is The Difference?
4.
Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity
5.
Case Study: Genomic Medicine in Precision Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
4.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation